Evaxion Biotech A/S (EVAX)
$1.19
-0.03 (-2.46%)
Rating:
Recommendation:
-
| Symbol | EVAX |
|---|---|
| Price | $1.19 |
| Beta | 0.663 |
| Volume Avg. | 0.65M |
| Market Cap | 31.442M |
| Shares () | - |
| 52 Week Range | 0.97-3.52 |
| 1y Target Est | - |
| DCF Unlevered | EVAX DCF -> | |
|---|---|---|
| DCF Levered | EVAX LDCF -> | |
| ROE | -106.65% | Strong Sell |
| ROA | -89.88% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 102.58% | Buy |
| P/E | -0.91 | |
| P/B | 2.09 | Strong Buy |
Latest EVAX news
About
Download (Excel)Dr. Niels Iversen Moeller M.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.